YM BioSciences Presents CYT387 Data at International Leukemia Conference

(PresseBox) ( Mississauga, Canada, )
YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), is presenting on its JAK1/2 inhibiting small molecule at the New Directions in Leukemia Research Conference in Queensland, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of YM BioSciences Australia Pty Ltd (formerly Cytopia). The presentation, "A novel, potent and selective dual inhibitor of JAK1 and JAK2 for treatment of myeloproliferative neoplasms" will be made on Tuesday, March 30th at 12:00 noon AEST.

Dr. Chris Burns, Research Director at YM Australia, will give the presentation on CYT387 which is currently being investigated in a Phase I/II clinical trial for myelofibrosis at Mayo Clinic, in Rochester, MN. The presentation describes preclinical data obtained for CYT387 including a description of some of the effects the compound elicits intracellularly as a consequence of inhibition of the JAK2 enzyme.

Additional information on the New Directions in Leukemia Research Conference is available at www.ndlrconference.com. The abstract for the presentation will be posted at www.ymbiosciences.com.

This press release may contain forwardlooking statements, which reflect the Company's current expectation regarding future events. These forwardlooking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forwardlooking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forwardlooking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that JAK 1/2 and the VDA molecule will generate positive efficacy and safety data in future clinical trials; AeroLEF® will continue to generate positive efficacy and safety data in future clinical trials; that and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forwardlooking statements, whether as a result of new information, future events or otherwise.
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an service@pressebox.de.